Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide.

Autor: Gao H; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Zhang W; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Li Z; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Liu W; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Liu M; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Zhuo Q; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Shi Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Xu W; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Zhou C; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Qin Y; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Xu J; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China., Chen J; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China., Yu X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yuxianjun@fudanpci.org.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yuxianjun@fudanpci.org.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yuxianjun@fudanpci.org.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. yuxianjun@fudanpci.org.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. yuxianjun@fudanpci.org., Xu X; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xuxiaowu@fudanpci.org.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xuxiaowu@fudanpci.org.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. xuxiaowu@fudanpci.org.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. xuxiaowu@fudanpci.org.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. xuxiaowu@fudanpci.org., Ji S; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. jishunrong@fudanpci.org.; Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. jishunrong@fudanpci.org.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. jishunrong@fudanpci.org.; Shanghai Pancreatic Cancer Institute, Shanghai, 200032, China. jishunrong@fudanpci.org.; Pancreatic Cancer Institute, Fudan University, Shanghai, 200032, China. jishunrong@fudanpci.org.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 Nov 07; Vol. 24 (1), pp. 1362. Date of Electronic Publication: 2024 Nov 07.
DOI: 10.1186/s12885-024-13117-5
Abstrakt: Background: Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).
Method: Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.
Results: In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p < 0.001).
Conclusion: Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje